Moneycontrol PRO
HomeNewsBusinessCompaniesAjanta Pharma launches generic asthma treatment tablets

Ajanta Pharma launches generic asthma treatment tablets

Ajanta Pharma USA Inc, a subsidiary of the company today announced the launch of Montelukast Sodium immediate release tablets in the strength of 10mg and Montelukast Sodium chewable tablets in 4mg & 5mg strengths, Ajanta Pharma said in a filing to BSE.

December 03, 2015 / 14:51 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Ajanta Pharma has launched its generic Montelukast Sodium tablets used for treatment of asthma and seasonal allergies in the American market. Ajanta Pharma USA Inc, a subsidiary of the company today announced the launch of Montelukast Sodium immediate release tablets in the strength of 10mg and Montelukast Sodium chewable tablets in 4mg & 5mg strengths, Ajanta Pharma said in a filing to BSE. The company's tablets are generic versions of Merck & Co Inc's Singulair tablets and Singulair chewable tablets respectively, it added.

    The United States Food & Drug Administration (USFDA) approval is for Montelukast offerings in three dosage forms (immediate-release tablets, chewable tablets and oral granules), Ajanta Pharma said. The company has five Abbreviated New Drug Application (ANDA) final approvals and two tentative approvals from the USFDA and 19 ANDAs are pending approval from the US health regulator, Ajanta Pharma said. Montelukast is used for prevention and chronic treatment of asthma, prevention of exercise induced bronchoconstriction and allergic rhinitis.

    Ajanta Pharma stock was trading at Rs 1,365.10, down 0.88 percent on the BSE.

    first published: Dec 3, 2015 02:51 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347